Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Glucose-dependent insulinotropic polypeptide induces lipolysis during stable basal insulin substitution and hyperglycaemia in men with type 1 diabetes: a randomized, double-blind, placebo-controlled, crossover clinical trial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Drug use in patients with short bowel syndrome and intestinal failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin - physiology and pharmacology

    Research output: Contribution to journalReviewResearchpeer-review

  3. LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Long-acting amylin analogues for the management of obesity

    Research output: Contribution to journalReviewResearchpeer-review

  5. Gastric Aspiration Improves Postprandial Glucose Tolerance Without Causing a Compensatory Increase in Appetite and Food Intake

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Glucose-dependent insulinotropic polypeptide (GIP) plays an important role in the glucose and lipid metabolism. We investigated the effects of exogenous GIP on lipid metabolism during time of stable insulin levels. Ten male patients with type 1 diabetes without endogenous insulin secretion (C-peptide-negative, mean [±SD] age 26 ± 4years, body mass index 24 [±2] kg/m2 , glycated haemoglobin 56 [±8] mmol/mol or 7.3 [±0.8]%) were studied in a randomized, double-blind, placebo-controlled, crossover study with continuous intravenous infusions of GIP (4 pmol/kg/min) or placebo (saline), during two separate 90-minute hyperglycaemic (12 mmol/L) clamps with basal insulin substitution (0.1-0.2 mU/kg/min). Plasma glycerol concentrations increased from baseline during GIP infusion and decreased during placebo infusion (baseline-subtracted area under the curve [bsAUC] 703 ± 407 vs. -262 ± 240 μmol/L × min, respectively; P < 0.001). Free fatty acids (FFAs) increased during GIP infusions (bsAUC 5505 ± 2170 μEq/L × min) and remained unchanged during placebo infusion (bsAUC -74 ± 2363 μEq/L × min), resulting in a significant difference between GIP and placebo infusions (P < 0.001). Plasma concentrations of glucose, insulin, glucagon-like peptide-1 and glucagon were similar during GIP and placebo infusions. GIP increased plasma glycerol and FFAs in patients with type 1 diabetes during hyperglycaemia and stable basal insulin levels. This supports a direct lipolytic effect of GIP at high glucose and low levels of plasma insulin.

Original languageEnglish
JournalDiabetes, Obesity and Metabolism
Volume24
Issue number1
Pages (from-to)142-147
Number of pages6
ISSN1462-8902
DOIs
Publication statusPublished - Jan 2022

    Research areas

  • antidiabetic drug, GIP, incretin physiology, insulin therapy, lipid-lowering therapy, type 1 diabetes

ID: 67568207